T cell receptor

A T cell receptor with high specificity for MAGE-A4 peptides addresses the challenge of inefficient targeting by binding selectively to HLA-A2 molecules, improving cancer therapy through enhanced binding affinity and therapeutic delivery.

JP7577149B2Active Publication Date: 2024-11-01ADAPTIMMUNE
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2023032695
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2016-04-08
Filing Date
2023-03-03
Publication Date
2024-11-01
Estimated Expiration
2037-04-10

AI Technical Summary

Technical Problem

Existing T cells lack specificity and efficiency in recognizing and targeting MAGE-A4 peptides presented by HLA-A2 molecules, leading to inadequate immune response in cancer therapy.

Method used

Development of a T cell receptor (TCR) with high specificity for the MAGE-A4 peptide GVYDGREHTV, which binds efficiently to HLA-A2 molecules while minimizing binding to the cross-reactive MAGE-B2 peptide, enhancing therapeutic efficacy.

Benefits of technology

The TCR demonstrates improved binding affinity and selectivity for MAGE-A4 peptides, enabling targeted delivery of cytotoxic agents to cancer cells and enhancing the effectiveness of adoptive cell therapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007577149000001
    Figure 0007577149000001
  • Figure 0007577149000002
    Figure 0007577149000002
  • Figure 0007577149000003
    Figure 0007577149000003
Patent Text Reader

Abstract

To provide T cell receptors (TCRs) that are highly specific for MAGE peptide / HLA-A2 antigen.SOLUTION: The present invention provides T cell receptors (TCRs) which bind the HLA-A*0201 restricted peptide GVYDGREHTV derived from the MAGE-A4 protein. The TCRs of the invention demonstrate excellent specificity profiles for the MAGE epitope.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a method for the production of melanoma-associated antigen (MAGE) A4 protein (amino acids 230-239). Previous HLA-A * T cell receptors that bind the 0201-restricted decapeptide GVYDGREHTV The TCR of the present invention has excellent specificity for this MAGE epitope. Gender profile is shown. [Background technology]

[0002] Cancer-testis antigens (CTAs) are a group of tumor-associated antigens (TAAs) encoded by approximately 140 genes. The expression of these antigens is localized in immune cells, such as the testis, placenta, and fetal ovaries. These genes are restricted to privileged sites; they are not normally expressed in other tissues. Expression of CTA has been observed in malignant tumors. The immunogenicity of CTA has been shown to be consistent with that of many solid tumors. These TAAs have led to the widespread development of cancer vaccines targeting these antigens. Among the large class of antigens, melanoma-associated antigens (MAGEs) are promising candidates for cancer immunotherapy. It is emerging as.

[0003] More than 30 cancer-testis (CT) genes are organized in a gene cluster on chromosome X. It has been reported as a member of a multigene family that has been reported (CT-X antigen). The gene cluster is located between Xq24 and Xq28 and is identified by MAGE and NY-ESO. The type I MAGE gene cluster is the most extensive and includes gene families such as IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-19, IL-21, IL-22 These include the MAGE-A, MAGE-B and MAGE-C families. MAGE-A proteins are derived from 12 different MAGE-A gene family members (MA MAGE-A1 to MAGE-A12) and are encoded by the MAGE homology domain (MHD MHD is defined by a conserved sequence of 165 to 171 amino acids called the Corresponding only to the region of amino acids shared by all MAGE-A family members do.

[0004] T cells recognize human leukocyte antigen ("HLA") or major histocompatibility complex ("MHC") They recognize and interact with complexes of peptides with cell surface molecules called peptide receptors. HLA / M antigens are derived from larger molecules that are processed by the cell and The interaction of T cells with HLA / peptide complexes is limited, and HLA molecules are also shown. and peptide combinations. In the absence of the partner complex, there will be no T cell response even if the partner complex is present. In the absence of a specific complex, there is no response, but T cells are present. They are involved in the immune system's response to diseases, autoimmune diseases, and in the response to disorders such as tumors. There are.

[0005] Some MAGE gene family proteins are expressed only in germ cells and cancer The others are widely expressed in normal tissues (MAGE-A to MAGE-C families). All these MAGE proteins are expressed in the endothelial cells (MAGE-D to MAGE-H). The family contains regions of close homology with other MAGE proteins and is involved in immune recognition. Thus, the desired M It is important to select TCR clinical candidates with high specificity for AGE peptides / HLA-A2 antigens It is.

[0006] MAGE A4 is a CTA member of the MAGE A gene family. It is It is thought to play a role in development, but its function is still unknown. In tumor pathogenesis, it appears to be involved in aspects of tumor transformation or tumor progression. GE A4 is a cancer that is associated with seminoma, congenital dyskeratosis, melanoma, hepatocellular carcinoma, renal cell carcinoma, pancreatic cancer, It has been implicated in a number of tumors, including lung, colon and breast cancer. VYDGREHTV (SEQ ID NO: 1) is the amino acid residues of the known MAGE-A4 protein. Corresponds to numbers 230 to 239.

[0007] MAGE B2 is a CTA of the MAGE B gene family. , is expressed in testis and placenta, as well as in a significant fraction of tumors of diverse histological types The peptide GVYDGEEHSV (SEQ ID NO: 2) shows cross-reactivity with MAGE A4. Thus, certain TCRs bind to HLA molecules presenting both peptides. You will be able to do this. Summary of the Invention

[0008] The present inventors have demonstrated that the MAGE A4 peptide GVYDGREH is preferentially expressed over MAGE B2. The present invention provides a TCR that binds to an HLA molecule presenting a T cell. , using a soluble form of the T cell receptor (TCR) at 25°C and pH between 7.1 and 7.5. With dissociation constants ranging from about 0.05 μM to about 20.0 μM as measured by plasmon resonance , HLA-A * Binds to GVYDGREHTV (SEQ ID NO: 1) complexed with 0201 a TCR having the property of beta chain variable domain, and the TCR variable domain is GVYDGREHTV (SEQ ID NO: 1) provides a TCR that forms contacts with at least residues V2, Y3 and D4 of

[0009] In an embodiment, the TCR according to the present invention is produced using a soluble form of the TCR at 25° C., pH 7.1. between 7.5 and 20 μM to 50 μM as measured by surface plasmon resonance GVYDGEEHSV (SEQ ID NO: 1) complexed with HLA-A*0201 with a dissociation constant of 2), wherein the TCR comprises a TCR alpha chain variable domain and a T In some embodiments, the dissociation constant is greater than 50 microM. For example, greater than 100 μM, 200 μM, 500 μM or more.

[0010] Therefore, the TCR according to the present invention is effective against HLA presenting GVYDGREHTV. It has the ability to bind efficiently to HLA-presenting GVYDGEEHSV. There is no ability to combine.

[0011] In some embodiments, the alpha chain variable domain of the TCR comprises the amino acid sequence of SEQ ID NO:3 (alpha chain). Acid sequence and / or the beta chain variable domain comprises an amino acid sequence having at least 80% identity to the amino acid sequence of SEQ ID NO: 4 (beta chain). acidity It contains an amino acid sequence having at least 80% identity to the sequence.

[0012] In a further aspect, the present invention relates to an HLA-A * A T cell receptor (TCR) having the property of binding to GVYDGREHTV (SEQ ID NO: 1) in complex with 0201, comprising a TCR alpha chain variable domain and a TCR beta chain variable domain, The alpha chain variable domain is acidity and / or The beta chain variable domain is represented by the amino acid sequence of SEQ ID NO:4. acidity A TCR is provided that comprises an amino acid sequence having at least 80% identity to the sequence.

[0013] The GVYDGREHTV HLA-A2 complex is a cancer tumor targetable by the TCR of the present invention. The present invention provides a method for delivering a cytotoxic or immune effector agent to a cancer cell. and / or for use in adoptive therapy. do.

[0014] The TCR is based on the International Immunogenetics and Targeted Targeted Cells (IMGT) TCR nomenclature and the IMGT publication of TCR sequences. The naturally occurring alpha-beta heterodimers are described with links to international databases. A monomelic TCR has an alpha chain and a beta chain. Generally, each chain contains a variable region , a joining region and a constant region, and the beta chain usually has a short segment between the variable region and the joining region. It also contains a diversity region, which is often considered to be part of the linkage region. Each variable region consists of three CDRs (complementarity determining regions) embedded within framework sequences. ), one of which is a hypervariable region designated CDR3. by CDR1 and CDR2 sequences and by a partially defined CDR3 sequence. There are several distinct types of alpha chain variable (Vα) regions and several types of beta The Vα types are designated by a unique TRAV number in the IMGT nomenclature. Therefore, "TRAV21" is conserved from TCR to TCR. However, it is partially defined by the amino acid sequence, which also contains amino acid sequences that differ from TCR to TCR. The unique framework and CDR1 and CDR2 sequences, as well as the CDR3 sequence, are defined as In a similar manner, "TRBV5-1" defines a TCR Vα region having a unique Define the TCR Vβ region with framework and CDR1 and CDR2 sequences but have only partially defined CDR3 sequences.

[0015] The junctional regions of the TCR are designated as constants by the unique IMGT TRAJ and TRBJ nomenclature. Regions are similarly defined by the IMGT TRAC and TRBC nomenclature.

[0016] The beta chain diversity region is referred to by the abbreviation TRBD in the IMGT nomenclature and is described above. Thus, concatenated TRBD / TRBJ regions are often considered together as linkage regions.

[0017] The α and β chains of the αβ TCR generally each consist of two “domains”, i.e. The variable domain is considered to have a variable domain and a constant domain. In the present specification and claims, "TCR alpha fragment" refers to a fragment of a TCR alpha fragment. The term "variable domain" therefore refers to the linkage of the TRAV and TRAJ regions, The term CR alpha constant domain refers to the extracellular TRAC region, or the C-terminal truncation Similarly, the term "TCR beta variable domain" refers to the TRAB sequence. The term TCR beta constant domain refers to the linkage of the V and TRBD / TRBJ regions. , the extracellular TRBC region, or the C-terminal truncated TRBC sequence.

[0018] The unique sequences defined by the IMGT nomenclature are well known to those skilled in the art of TCR. For example, they can be found in the IMGT public database. "T cell Receptor Factsbook", (2001) LeFranc and LeFranc, Academic Press, ISBN 0-12-441352-8 also discloses sequences defined by the IMGT nomenclature. However, due to the publication dates and resulting time lags, the information therein may at times differ from the Verification by reference to the GT database is required.

[0019] One TCR according to the invention is shown in SEQ ID NO:2 (TRAV10+TRAC). Such an alpha chain extracellular domain and SEQ ID NO:3 (TRBV24-1+TRBC-2) "Parent TCR", "Parent MAGE-A The terms "TCR" and "TCR2" are used interchangeably herein and refer to SEQ ID NOs: 2 and 3 and The term refers to the TCR with its respective extracellular alpha and beta chains. A parent TCR that has a higher affinity for coalescence and / or a slower dissociation rate than the parent TCR It would be desirable to provide a TCR that is mutated or modified relative to

[0020] The binding profiles of these mutated or modified TCRs can be compared. For the purposes of providing a reference TCR, the parent MAGE-A4 TCR allele shown in SEQ ID NO:3 The extracellular sequences of the Fa chain and the parent MAGE-A4 TCR beta chain are shown in SEQ ID NO:4. It is advantageous to use a soluble TCR according to the invention having an extracellular sequence of R is referred to herein as the "reference TCR" or the "reference MAGE-A4 TCR." SEQ ID NO:5 contains the parent alpha chain extracellular sequence of SEQ ID NO:3 and also contains the T162 (i.e. Note that T48 in TRAC has been replaced by C162. SEQ ID NO:6 is the parent beta chain extracellular sequence of SEQ ID NO:4 and also S169 (i.e., T RBC2 S57) is replaced by C169, C187 is replaced by A187, and N20 1 to D201. These cysteine ​​substitutions, relative to the cysteine ​​substitutions, result in a refolded soluble TCR, i.e. TCs formed by refolding extracellular alpha and beta chains This allows for the formation of interchain disulfide bonds that stabilize R. By using the purified soluble TCR as the reference TCR, the binding affinity and binding half-life were determined. This allows for more convenient evaluation of the TCR. The TCR of the present invention may contain the above mutations. .

[0021] The TCRs of the present invention may be non-naturally occurring and / or may be purified and / or modified. The TCRs of the present invention may have two or more mutations present in the alpha and / or beta chain variable domains relative to a parent TCR. "Modified TCR" and "mutant TCR" are used interchangeably herein and generally refer to a TCR that has one or more mutations introduced, particularly within its alpha and / or beta chain variable domains, relative to a parent TCR. These mutations may be associated with HLA-A *In certain embodiments, there are 1, 2, 3, 4, 5, 6, 7 or 8 mutations, such as 4 or 8 mutations, in the alpha chain variable domain and / or 1, 2, 3, 4 or 5 mutations, such as 5 mutations, in the beta chain variable domain. In some embodiments, the alpha chain variable domain of the TCR of the present invention comprises the amino acid sequence of SEQ ID NO:3. acidity In some embodiments, the beta chain variable domain of the TCR of the present invention may comprise an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity to the amino acid sequence of SEQ ID NO:4. acidity It may comprise an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity to the sequence.

[0022] The alpha chain variable domain of the TCR of the present invention is shown in SEQ ID NO:3 with reference to the numbering. In light of [Table 1] and / or The beta chain variable domain is represented by the numbering shown in SEQ ID NO:4. [Table 2] The nucleic acid may have at least one of the following mutations:

[0023] The alpha chain variable domain of the TCR of the present invention is Amino acid sequence from amino acid residues 1 to 105 or whose amino acid residues 1 to 27, 34 to 47, and 54 to 90 are SEQ ID NO:3, or 5 or 7-8 sequences of amino acid residues 1-27, 34-47, and 54-90 and has at least 90% or 95% identity to amino acid residues 28 to 33, 8 to 53 and 91 to 105 are amino acids of SEQ ID NO: 3, 5, or 7 to 8, respectively At least 90% or more of the sequences of residues 28-33, 48-53, and 91-105 is an amino acid sequence with 95% identity may also include

[0024] In the alpha chain variable domain (i) the sequence of amino acid residues 1 to 26 is: (a) amino acid residues 1 to 26 of SEQ ID NO:3 or (b) has at least 90% identity to the sequence of (a). have one, two or three amino acid residues inserted or deleted relative to the sequence It is okay to (ii) the sequence of amino acid residues 28 to 33 is VSPFSN; (iii) the sequence of amino acid residues 33 to 49 is: (a) amino acid residue 3 of SEQ ID NO:3 4 to 47, or (b) One, two or three amino acid residues are inserted or deleted relative to the sequence in a) may have a group, (iv) The sequence of amino acid residues 48 to 53 is LTIMTF or LTRMTF or L may be TIVTF or LTILTF, (v) the sequence of amino acid residues 55 to 89 is the sequence of amino acid residues 54 to 90 of SEQ ID NO:3. It may have at least 90% identity to the sequence or relative thereto. may have one, two or three insertions, deletions or substitutions in (vi) The sequence of amino acids 90 to 93 may be CVVSGGTDSWGKLQF. stomach.

[0025] The beta chain variable domain of the TCR of the present invention is selected from the group consisting of amino acids 4, 6 and 9 of SEQ ID NO: ...5. Acid sequence or the amino acid residues 1 to 45, 51 to 67, and 74 to 109 are each SEQ ID NO: 4 or 9 amino acid residues 1 to 45, 51 to 67, and 74 to 109 of the sequence 90% or 95% identity, and 9 to 123 are amino acid residues 46 to 50, 68 to 73, and 69 of SEQ ID NO: 4 or 9, respectively. and 109-123, which have at least 90% or 95% identity to the sequence Acid sequence may also include

[0026] In the beta chain variable domain (i) the sequence of amino acid residues 1 to 45 is: (a) the sequence of amino acid residues 1 to 45 of SEQ ID NO:4 or (b) has at least 90% identity to the sequence of (a). have one, two or three amino acid residues inserted or deleted relative to the sequence It is okay to (ii) the sequence of amino acid residues 46 to 50 may be KGHDR; (iii) the sequence of amino acid residues 51 to 67 is: (a) amino acid residue 5 of SEQ ID NO:4 1 to 67, or (b) One, two or three amino acid residues are inserted or deleted relative to the sequence in a) may have a group, (iv) the sequence of amino acid residues 68 to 73 may be SVFDK; (v) the sequence of amino acid residues 54 to 90 thereof is: (a) amino acid residues 54 to 90 of SEQ ID NO: 4 90 sequences, or (b)(a) One, two or three amino acid residues are inserted or deleted relative to the sequence of may have (vi) the sequence of amino acids 109 to 123 is CATSGQGAYNEQFF or CA TSGQGAYREQFF.

[0027] The TCR of the present invention comprises one of the following combinations of alpha and beta chain variable domains: May have one of: [Table 3]

[0028] The phenotypically silent barrier of any of the TCRs of the invention disclosed herein As used herein, "phenotypically silent" refers to a gene that is capable of expressing a phenotypically silent gene. The term "variant" refers to any of the above with one or more additional amino acid changes. and having a similar phenotype to a corresponding TCR that does not contain said alteration. For the purposes of this application, the TCR phenotype includes the antigen binding specificity ( K D and / or binding half-life) and antigen specificity. The variants were measured under identical conditions (e.g., at 25°C on the same SPR chip). and the measured K of the corresponding TCR that does not contain the modification. D and / or one of the binding half-lives Within 0%, GVYDGREHTV (SEQ ID NO: 1) HLA-A * For 0201 complex RuK D and / or binding half-life. Suitable conditions are as described in Example 3. Antigen specificity is further defined below. As mentioned above, GVYDGREHTV (SEQ ID NO: 1) HLA-A * Correlation with 0201 complex Without changing the affinity for the interaction, the definition is TCRs can be generated that incorporate alterations within the constant and / or variable domains In particular, such silent mutations are known not to be directly involved in antigen binding. Such minor variations may be incorporated within the portions of the sequences that are provided (e.g., outside the CDRs). Variants of the T are included within the scope of the present invention. CR also forms part of the present invention.

[0029] Mutations were determined using PCR-based and restriction enzyme-based cloning. cloning, or ligation-independent cloning (LIC) procedures, This can be done using any suitable method, including but not limited to, many standard methods. Polymerase chain reaction (PCR) and restriction For more information about enzyme-based cloning, see Sambrook & Ru ssell,(2001)Molecular Cloning - A Labora See the Library Manual (3rd Ed.) CSHL Press. For more information on the gate-independent cloning (LIC) procedure, see Rasht et al. Chian, (1995) Curr Opin Biotechnol 6(1):30 -6.

[0030] The TCR of the present invention is the MAGE-A4 peptide, GVYDGREHTV (SEQ ID NO: 1). The TCR of the present invention has the property of binding the HLA-A2 complex. It was found that the specificity for the MAGE epitope was high relative to the MAGE epitope. Thus, therapeutic or diagnostic agents can be targeted to cells and tissues that display the epitope. The present invention is particularly suitable as a targeting vector for delivering excitable markers. Specificity in the context of TCR is negative for peptide GVYDGREHTVHL AA * 0201 target cells, or presenting the MAGE B2 peptide GVYDGEEHSV The peptide GVYDG has a very low ability to recognize HLA cells that HLA-A positive for REHTV * TCR of the present invention that recognizes target cells To test for specificity, the TCR may be in soluble form and / or or expressed on the surface of a T cell. Recognition occurs in the presence of a TCR and a target cell. In this case, the level of T cell activation can be determined by measuring the level of T cell activation induced by the peptide. Negative or minimal recognition of MAGE B2 target cells when measured under the same conditions Less than 10%, preferably less than 5%, of the level produced in the presence of peptide-positive target cells More preferably, the level of T cell activation is defined as less than 1%. For TCRs, specificity can be determined at therapeutically relevant TCR concentrations. The concentration is 10 -9 As TCR concentrations below M and / or the corresponding EC 50 Value A peptide positive control may be defined as a concentration up to 100 times higher, preferably up to 1000 times higher. The sex cells may be obtained by pulsing with the peptide or, more preferably, Preferably, said peptides are present in a naturally occurring manner. Both the peptide-negative cells and the peptide-negative cells are human cells.

[0031] Certain TCRs of the present invention have been found to be highly suitable for use in adoptive therapy. Such TCRs have been reported to have a potency of less than 200 μM, for example, from about 0.05 μM to about 20 μM. M or K for the complex up to about 100 μM D and / or about Binding half-life (T) for the complex ranges from 0.5 seconds to approximately 12 minutes. 1 / 2 ) In some embodiments, the TCRs of the present invention may be present at about 0.05 μM to about 20 μM, K for the complex from about 0.1 μM to about 5 μM or from about 0.1 μM to about 2 μM D Without wishing to be bound by theory, therapeutic benefits in adoptive cell therapy may include There appears to be an optimum window of affinity for TCRs with the use of epitopes from tumor antigens. Naturally occurring TCRs that recognize IgG1 generally have too low affinity (20 μM to 50 μM). Micromolar (M), extremely high affinity TCRs (in the nanomolar range or higher) interact with It has the problem of differential reactivity (Robbins et al (2008) J. Immunol. 180 6116-6131;Zhao et al(2007) J. Immunol. 179 5845-5854;Scmid et al(2010)J.Immunol 184 4936-4946).

[0032] The TCRs of the present invention may be αβ heterodimers or may be in a single chain format. Single chain formats include Vα-L-Vβ, Vβ-L-Vα, Vα-Cα-L-Vβ or Vα-L - an αβTCR polypeptide of the Vβ-Cβ type, where Vα and Vβ are TCRα variable region and TCRβ variable region, and Cα and Cβ are TCRα constant region and TCRβ constant region, respectively. and the TCRβ constant region, and L is a linker sequence. For use as a targeting agent to target TCRs, soluble forms (i.e., transmembrane For stability, the soluble The heterodimeric αβ TCR can be used as described, for example, in WO03 / 020763. In addition, it is preferred to have disulfide bonds introduced between residues of each constant domain. Preferably, one or both of the constant domains present in the αβ heterodimer of the present invention are For example, at most 15, or at most 10, or at most 8, or more The polypeptide may be truncated at the C-terminus by only a few amino acids. Use in Adoptive Therapy For this purpose, αβ heterodimeric TCRs, for example, have cytoplasmic and transmembrane domains The vector may be transfected as a full-length strand carrying both the nucleotides. In nature, TCRs for each of these antigens consist of alpha and beta constant domains. and may additionally contain a disulfide bond consistent with that found between Or alternatively, non-naturally occurring disulfide bonds may be present.

[0033] As will be apparent to one of skill in the art, the present invention can be used to enhance the binding properties of the TCR without substantially affecting its binding properties. A given sequence may be split at its C-terminus and / or N-terminus into one, two, three, four, five or more amino acids. It may be possible to truncate only the above residues. All these minor barriers The compounds are encompassed by the present invention.

[0034] The alpha-beta heterodimeric TCRs of the invention typically comprise an alpha chain TRAC constant domain. The alpha chain TRBC1 or TRBC2 constant domain sequence and the beta chain TRBC1 or TRBC2 constant domain sequence. The chain and beta chain constant domain sequences are located between Cys4 in exon 2 of TRAC and TRBC1. or Cys2 in exon 2 of TRBC2 to eliminate the native disulfide bond between The alpha and base chains may be modified by truncation or substitution for The TA chain constant domain sequence is Thr48 of TRAC and S of TRBC1 or TRBC2. The cysteine ​​residue at er57 may be substituted, and the cysteine ​​residue at er57 may be modified. In is a disulfide bond between the alpha and beta constant domains of the TCR. Form.

[0035] Some TCRs of the invention have substantially higher potency than the reference MAGE-A4 TCR. GVYDGREH Binding affinity and / or binding affinity for the TV-HLA-A2 complex Increasing the binding affinity of the native TCR to its peptide-MHC ligand The specificity of the TCR for the target antigen is often reduced. This is due to the fact that Zhao Yangbing et al.,The Journal of Immunology,The Ame rican Association of Immunologists,US,vo l.179, No. 9, 1 November 2007, 5845-5854 However, the TCRs of the present invention derived from the parent TCRs have substantially higher cloning ability than the parent TCRs. Although it has high binding affinity to the TV-HLA-A2 complex, Moreover, they maintain specificity for MAGE over MAGE-B2. -A4 is significantly (eg, at least 10-fold) selective for the parental TCR.

[0036] Binding affinity (equilibrium constant K D ) and binding half-life (T 1 / 2 (expressed as , as determined using the surface plasmon resonance (BIAcore) method of Example 3 herein. Measurements can be performed at 25°C and pH 7.1 to 7.5 using soluble TCR. Doubling the affinity of the TCR results in D It will be understood that this will be halved. T 1 / 2 is the dissociation rate (k off ) is calculated as ln2 divided by I mean, T 1 / 2 is doubled, resulting in k off is halved. K for TCR D and k off Values ​​are usually obtained for soluble forms, i.e., truncated and hydrophobic transmembrane domains. The IgG antibody titer is measured on a form of the TCR in which the IgG residues have been removed. If the soluble form of the TCR fulfills the requirements, it is GVYDGREHTV- The need to have a binding affinity and / or binding half-life for the HLA-A2 complex It should be understood that the conditions are met. Preferably, the binding affinity or The binding half-life should be measured several times, e.g., three or more times, using the same assay protocol. The reference MAGE-A4 TCR is measured by the method. When the D and koff is about 0.73 / sec (i.e., T 1 / 2 is approximately 0.95 seconds).

[0037] In a further aspect, the present invention provides a nucleic acid encoding a TCR of the present invention. In some embodiments, the nucleic acid is a cDNA. In some embodiments, the present invention provides a nucleic acid comprising a sequence encoding an alpha chain variable domain of the The present invention provides a nucleic acid comprising a sequence encoding the β chain variable domain of the TCR of the present invention. may be non-naturally occurring and / or purified and / or modified. It may be possible.

[0038] In another aspect, the present invention provides a vector comprising the nucleic acid of the present invention. The target is a TCR expression vector.

[0039] The present invention also provides a cell harboring a vector of the present invention, preferably a TCR expression vector. Vectors can contain a single open reading frame or two different open reading frames. The present invention provides a method for the preparation of a nucleic acid sequence encoding an alpha chain and a beta chain in the same reading frame. Another embodiment may comprise a nucleic acid encoding the alpha chain of the TCR of the present invention. a first expression vector comprising a nucleic acid encoding the beta chain of a TCR of the present invention; Cells harboring a second expression vector are provided. Such cells are particularly useful in adoptive therapy. The cells of the invention may be isolated and / or recombinant and / or Or it may be non-naturally occurring and / or modified.

[0040] Since the TCRs of the invention have utility in adoptive therapy, the invention also includes the TCs of the invention. Non-naturally occurring and / or purified and / or modified cells displaying R. The present invention relates to a method for the treatment of T cells, in particular T cells, which present the TCR of the present invention. Populations are also provided. Nucleic acids (such as DNA, cDNA or RNA) encoding the TCRs of the invention. There are several methods suitable for transfecting T cells with IgG (see, for example, Robb et al., Transfection of T cells with IgG ins et al.,(2008)J Immunol.180:6116-6131 The T cells expressing the TCR of the present invention can be used for adoptive therapy-based cancer treatment. As will be known to those skilled in the art, adoptive therapy may be performed. There are several suitable methods that can be used (e.g., Rosenberg et al., 2008) Nat Rev Cancer 8(4):299-308 .

[0041] The soluble TCR of the present invention has detectable binding to antigen-presenting cells and tissues containing antigen-presenting cells. These are useful for delivering a label or therapeutic agent that can be used to treat cancer. - the TCR is used to detect the presence of cells presenting the HLA-A2 complex, a detectable label (for diagnostic purposes); a therapeutic agent; or a PK modification (e.g., by pegylation). It may be attached (covalently or otherwise) to a moiety.

[0042] Detectable labels for diagnostic purposes include, for example, fluorescent labels, radiolabels, enzymes, nucleic acids, etc. Probes and contrast agents are included.

[0043] Therapeutic agents that can be bound to the TCR of the present invention include immunomodulators, radioactive compounds, enzymes ( Toxic effects include inflammatory bowel disease (e.g., perforin) or chemotherapeutic agents (e.g., cisplatin). To ensure that the toxin is delivered to the desired site, the compound is released slowly. It may be in a liposome linked to the TCR for release in the body. This prevents the damaging effects of TCR binding to the relevant antigen-presenting cells during transport. This ensures that the toxin will have the most effective effect later.

[0044] Other suitable therapeutic agents include: Small molecule cytotoxic agents, i.e., those having a molecular weight of less than 700 Daltons and capable of inducing an immune response to mammalian cells Compounds that have the ability to kill bacteria. Such compounds include compounds that have the ability to have cytotoxic effects. In addition, these small molecule cytotoxic agents may include prodrugs and toxic metals. compounds that decay or are transformed under physiological conditions to release cytotoxic agents. Examples of such agents include cisplatin, melanoma, and the like. Itansine derivatives, rachemicin, calicheamicin, docetaxel, etoposide, Gemcitabine, ifosfamide, irinotecan, melphalan, mitoxantrone, sol Sorfimer sodium photofrin II in II), temozolomide, topotecan, trimetrate glucuronate (trime treate glucuronate), auristatin E vincristine and doxorubicin Contains xorubicin; Peptide cytotoxins, i.e. proteins capable of killing mammalian cells or fragments thereof, such as ricin, diphtheria toxin, Pseudomonas exotoxin A, DNA ase and RNase; Radionuclides, i.e., alpha or beta particles, or gamma rays, or a combination of both. An unstable isotope of an element that decays with the simultaneous release of ions. For example, iodine-131, le Nitrium 186, Indium 111, Yttrium 90, Bismuth 210 and 213, Aluminium 225 and astatine 213; for high affinity TCR or its multimers Chelating agents may be used to facilitate binding of these radionuclides; Immunostimulants, i.e. immune effector molecules that stimulate the immune response, e.g., IL-1 -2 and cytokines such as IFN-γ · Superantigens and their variants; · TCR-HLA fusion; Chemokines, e.g., IL-8, platelet factor 4, melanoma growth stimulatory protein, etc. ; Anti-T cell or anti-NK cell determinant antibodies (e.g., anti-CD3, anti-CD28 or anti- an antibody or fragment thereof, comprising a nucleotide sequence corresponding to the nucleotide sequence of the antibody or fragment thereof, and Alternative protein scaffolds with antibody-like binding properties · Complement activator; Heterologous protein domains, allologous protein domains, viral / bacterial Protein domains, viral / bacterial peptides Includes:

[0045] A preferred embodiment is an anti-CD3 antibody, or a functional fragment or fragment of said anti-CD3 antibody. are variants (usually by fusion to the N- or C-terminus of the alpha or beta chain). The compositions and methods described herein are provided by the TCRs of the invention linked to the TCRs. Antibody fragments and variants / analogues suitable for use in the Fab fragments, F(ab')2 fragments, dsFv and scFv fragments, Nanobodies These constructs are commercially available from Ablynx (Belgium) Lactococci are synthetic monoimmunoglobulins derived from camelid (e.g., camel or llama) antibodies. Brin variable heavy chain domain) and domain antibodies (Domantis (Belgium um), affinity matured single immunoglobulin variable heavy chain domains or immunoglobulins or alternative protein scaffolds that exhibit antibody-like binding properties, For example, Affibodies (Affibody (Sweden), modified Protein A scaffold) or Anticalins (Pieris (German ), including modified anticalins).

[0046] For some purposes, the TCRs of the invention may be aggregated into complexes containing several TCRs. The multivalent TCR complex may be formed by combining the two. There are several human proteins that contain multimerization domains that can be used to synthesize tetramers of p53. The monoclonal domain, which provides increased serum persistence and reduced dissociation rate compared to monomeric scFv fragments. It has been used to generate tetramers of scFv antibody fragments, which show a marked reduction in lluda et al.(2001)J.Biol.Chem.276(17)143 Hemoglobin is also a tetramerized form that could potentially be used for this type of application. The multivalent TCR complexes of the invention comprise a non-multimeric wild type or TCR of the invention. GVYDGREHTV HLA-A2 complexes compared to cell receptor heterodimers Thus, the multivalent complexes of the TCRs of the present invention may also have enhanced binding ability. Such multivalent TCR complexes according to the invention are included within the scope of the present invention. Tracking or targeting cells presenting specific antigens in vivo and for the generation of further multivalent TCR complexes having such uses. It is also useful as an intermediate.

[0047] As is well known in the art, TCRs can undergo post-translational modifications. Glycosylation is one such modification, which modifies defined amino acids in the TCR chains. Covalent attachment of an oligosaccharide moiety to a saccharide residue, e.g., an asparagine residue, or Serine / threonine residues are well-known sites for oligosaccharide addition. The glycosylation state of a protein depends on the protein sequence, the protein conformation and the specific enzyme. In addition, the glycosylation status (i.e., The oligosaccharide type, covalent linkages and total number of attachments can affect protein function. When producing recombinant proteins, it is often desirable to control glycosylation. Controlled glycosylation has been used to improve antibody-based therapeutics. efferis R.,Nat Rev Drug Discov.2009 Mar; 8(3):226-34.) For the soluble TCRs of the present invention, glycosylation is In vivo, for example by using specific cell lines, or in vitro Glycosylation may be controlled by chemical modification to improve pharmacokinetics, immunosuppression, and It is possible to reduce pathogenicity and more closely mimic the native human protein. Such modifications are desirable because they S.,Pharm Sci.2005 Aug;94(8):1626-35).

[0048] For administration to a patient, a composition of the invention (usually coupled to a detectable label or therapeutic agent) is The TCR, nucleic acid and / or cells may be administered in a pharmaceutical formulation together with a pharma- ceutical acceptable carrier or excipient. The therapeutic or imaging TCRs according to the invention may be provided in a composition. It is supplied as part of a sterile pharmaceutical composition, which will normally include a pharma- ceutically acceptable carrier. The pharmaceutical composition may be administered in any suitable form (depending on the desired method of administering it to a patient). It may be in any suitable form. It may be provided in unit dosage form, generally in a sealed container. The composition may be provided in a separate container and may be provided as part of a kit. Kits will usually (but not necessarily) include instructions for use. It may contain a plurality of said unit dosage forms.

[0049] The pharmaceutical compositions can be administered by any suitable route, preferably parenterally (subcutaneously, intramuscularly, or preferably Such compositions may be formulated for administration by any route, including intravenous or intravenous. The active ingredient may be mixed with the carrier under sterile conditions by any method known in the art. Or it can be prepared by mixing with an additive.

[0050] The dosage of the substance of the invention will depend on the disease or disorder being treated, the age and condition of the individual being treated. The dosage may vary widely depending on the individual and the physician has the final say on the appropriate dosage to be used. This will be the case.

[0051] The TCRs, pharmaceutical compositions, vectors, nucleic acids and cells of the invention may be prepared in substantially pure form, For example, at least 80%, at least 85%, at least 90%, at least 91%, At least 92%, at least 93%, at least 94%, at least 95%, at least At least 96%, at least 97%, at least 98%, at least 99% or 100% pure may be provided.

[0052] Further provided by the present invention are: For use in medicine, preferably against cancer, e.g. solid tumors (e.g. lung, For use in methods of treating cancer of the liver and stomach) and / or squamous cell carcinoma, etc. The TCR, nucleic acid or cell of the present invention. Use of the TCR, nucleic acid or cell of the invention in the manufacture of a medicament for treating cancer. For. administering to the patient a TCR, nucleic acid or cell of the invention. How to treat.

[0053] Preferred features of each aspect of the invention may be taken as referring to each of the other aspects mutatis mutandis. The prior art documents referred to in this specification are protected by law. These specifications are incorporated to the maximum extent permitted by law.

[0054] The invention is further described in the following non-limiting examples.

[0055] Reference is made to the attached sequence, in which: SEQ ID NO:1 is the MAGE A4 peptide SEQ ID NO:2 is the MAGE B2 peptide

[0056] SEQ ID NO:3 is the amino acid sequence of the extracellular part of the alpha chain of the parent MAGE-A4 specific TCR. and SEQ ID NO: 4 is the vector of the parent MAGE-A4 specific TCR beta chain amino acid sequence. The amino acid sequence of the extracellular portion of the data chain is shown.

[0057] SEQ ID NO:5 is a reference TCR for the naturally occurring Lenti T The amino acid sequence of the alpha chain of CR is shown. The sequence is T162 (i.e., TRAC constant region The sequence is the same as that of the parent TCR except for a cysteine ​​substitution at T48 in the sigma-specific domain. Number 6 is the reference TCR of the native Lenti TCR (herein referred to as the "reference TCR"). The sequence is a beta chain with a cysteine ​​at S169 (i.e., S5 of the TRBC2 constant region). 7) is replaced by, A187 is replaced by C187, and D201 is replaced by N201. It is the same as that of the parent TCR except for

[0058] SEQ ID NOs: 7 and 8 show the sequences of the alpha chain which may be present in the TCR of the present invention. Subsequences making up the R regions, or substantial portions of the CDR regions, are underlined.

[0059] SEQ ID NO: 9 shows the sequence of a beta chain that may be present in the TCR of the present invention. Subsequences comprising, or substantial portions of, the CDR regions are underlined.

[0060] SEQ ID NOs: 10 to 15 are the soluble alpha and beta chains of TCR A, B and C. Any of these TCRs can be developed into a functional TCR according to the present invention. It was not possible. EXAMPLES

[0061] [Example 1] Reference MAGE-A4 TCR alpha chain and Cloning of beta chain variable region sequences The parent MAGE-A4 TCR variable alpha domain of SEQ ID NOs: 3 and 4, respectively, and TCR variable beta domains were expressed based on pGMT7 containing either Cα or Cβ In the plasmid, (Sambrook and Russell, Molecular Cloning a Laboratory Manual Third edition Plasmids were cloned by standard methods described in App Using the Lied Biosystems 3730xl DNA Analyzer The reference MAGE-A4 TCR variable alleles of SEQ ID NOs: 4 and 5, respectively, were sequenced. The lufa domain and the TCR variable beta domain were cloned in a similar manner.

[0062] The DNA sequence encoding the TCR alpha chain variable region was digested with restriction enzymes and then purified using pEX The DNA sequence encoding the TCR beta chain variable region was It was ligated into pEXb21, which had also been cut with the restriction enzymes.

[0063] The ligated plasmid was transformed into competent E. coli strain XL1 Transformed into -blue cells and plated on LB / agar containing 100 μg / mL ampicillin. After overnight incubation at 37°C, single colonies were picked and Grow overnight at 37°C with shaking in 5 mL LB containing 100 μg / mL ampicillin. The cloned plasmid was purified using a Miniprep kit (Qiagen). Plasmids were purified using the Applied Biosystems 3730x l Sequenced using a DNA Analyzer.

[0064] [Example 2] Expression, refolding and purification of soluble reference MAGE-A4 TCR Expression plasmids containing the reference TCR α and β chains, respectively, as prepared in Example 1. The plasmids were transformed separately into E. coli strain BL21pLysS to produce a single ampicillin-resistant The viable colonies were approximately 0.6-0.5% in TYP (ampicillin 100 μg / ml) medium at 37°C. OD of 8 600 After incubation for 1 h, protein expression was induced with 0.5 mM IPTG. Three hours after transfection, the cells were incubated at 4000 rpm for 30 min in a Beckman J-6B. The cells were then collected by centrifugation at 37 °C for 1 h. The cell pellet was diluted with 10% MgCl2 and DNase I. The inclusion body pellet was dissolved in 25 ml of Bug Buster (NovaGen) at 4°C. The samples were centrifuged at 13,000 rpm for 30 minutes in a Beckman J2-21 centrifuge. Then, three detergent washes were performed to remove cell debris and membranes. The components were removed. The inclusion body pellet was washed with Triton buffer (50 mM Tri is-HCI pH8.0, 0.5% Triton-X100, 200mM NaCl , 10 mM NaEDTA) and then homogenized in a Beckman J2-21 The pellet was then pelleted by centrifugation at 13,000 rpm for 15 minutes in a centrifuge. Buffer: 50 mM Tris-HCl pH 8.0, 1 mM NaEDTA The detergent and salt were removed by washing in the same manner. Finally, the inclusion bodies were isolated from 30 mg of The inclusion body protein yield was determined by aliquoting and freezing at -70°C. The OD measurements were performed using a Hitachi U-2001 spectrophotometer. The protein concentration was then calculated using the extinction coefficient.

[0065] Approximately 15 mg of TCR α chain and 15 mg of TCR β chain solubilized inclusion bodies were obtained from frozen stocks. The tubes were thawed from the tube and 10 ml of guanidine solution (6 M guanidine hydrochloride) was added to ensure complete strand denaturation. anidine, 50 mM Tris HCl pH 8.1, 100 mM NaCl, 10 mM Fully reduced and denatured TCR chains were diluted in 10 mM EDTA, 10 mM DTT. The guanidine solution containing - 100mM Tris pH 8.1, 400mM L-arginine, 2mM EDT A, injected in 5 M urea. Redox couple (cysteamine hydrochloride and cystamine dihydrochloride). ) was added to a final concentration of 6.6 mM and 3.7 mM, respectively, and after approximately 5 minutes, the denatured The refolded TCR chains were added. The solution was left for about 30 minutes. TCR was measured using Spectrapor1 membrane (Spectrum; product no. 13267 0) was dialyzed against 10 L of H2O for 18-20 hours. After this time, The buffer was exchanged twice into fresh 10 mM Tris pH 8.1 (10 L) and dialyzed. The incubation was continued for approximately another 8 hours at 5°C ± 3°C.

[0066] Soluble TCR was purified by ion exchange using POROS 50HQ anion exchanger. The bound and unbound proteins were purified by loading them onto a conversion column in an Äkta purification apparatus (G E Healthcare) over 50 column volumes of 10 mM Tris p Degradation products and entrapment products were isolated by elution with a gradient of 0 to 500 mM NaCl in H8.1. Peak fractions were pooled and incubated with a cocktail of protease inhibitors (Cal The pooled fractions were then stored at 4°C and purified by Coomassie Biochem. The resulting products were analyzed by SDS-PAGE stained with 1,000 ng / ml of 1 ... Specifically, soluble TCR was prepared using GE Healthcare pre-equilibrated in PBS buffer (Sigma). Purified and purified using a healthcare Superdex 75HR gel filtration column. The peak eluting at a relative molecular weight of approximately 50 kDa was pooled and characterized using BIA. The cores were concentrated prior to characterization by surface plasmon resonance analysis.

[0067] [Example 3] Binding characterization BIAcore analysis The surface plasmon resonance biosensor (BIAcore 3000™) detects soluble It can be used to analyze the binding of a TCR to its peptide-MHC ligand. This is immobilized on a streptavidin-coated binding surface (sensor chip). By generating soluble biotinylated peptide-HLA ("pHLA") complexes that can be The sensor chip detects the T cell receptor for four different pHLA complexes. Contains four separate flow cells that allow simultaneous measurement of binding of pHLA complexes Manual injection of allows easy manipulation of precise levels of immobilized class I molecules It becomes.

[0068] Biotinylated class I HLA-A * The 0201 molecule is a constituent subunit protein In vitro reformulation of bacterially expressed inclusion bodies containing proteins and synthetic peptides. was then purified and enzymatically biotinylated in vitro. (O'Callaghan et al.(1999)Anal.Biochem.26 6:9-15). HLA-A * The 0201 heavy chain is expressed as a protein in the appropriate construct. Expressed with a C-terminal biotinylation tag that replaces the transmembrane and cytoplasmic domains of Expression levels of approximately 75 mg of inclusion bodies per liter of bacterial culture were obtained. C light chain or β2-microglobulin was also expressed in Escherichia coli from the appropriate constructs. The enzyme was expressed as a single unit at a level of approximately 500 mg per liter of bacterial culture.

[0069] E. coli cells were lysed and the inclusion bodies were purified to a purity of approximately 80%. The protein was prepared in 6 M guanidine-HCl, 50 mM Tris pH 8.1, 100 mM N aCl, 10 mM DTT, 10 mM EDTA, 0.4M L-arginine 100 mM Tris pH 8.1, 3.7 mM cystamine dihydrochloride, 6.6 mM Cysteamine hydrochloride, HLA-A * 02 molecule loading required 4mg / L MA GE-A4 GVYDGREHTV or MAGE-B2 GVYDGEEHSV peptide The denatured protein was analyzed at a concentration of 30 mg / L heavy chain and 30 mg / L β2m in the eluate. Refolding was performed by adding a single pulse of protein to the refolding buffer at <5°C. Refolding was allowed to reach completion for at least 1 hour at 4°C. It was made possible to do so.

[0070] The buffer was exchanged by dialysis into 10 volumes of 10 mM Tris pH 8.1. Two changes of buffer were required to sufficiently reduce the ionic strength of the solution. The protein solution was then passed through a 1.5 μm cellulose acetate filter. The eluate was filtered and loaded onto a POROS 50HQ anion exchange column (8 ml bed volume). Proteins were purified using an Akta purification system (GE Healthcare). Eluted with a linear 0-500 mM NaCl gradient in 10 mM Tris pH 8.1. HLA-A * The 0201-peptide complex was eluted at approximately 250 mM NaCl and Peak fractions were collected and supplemented with a cocktail of protease inhibitors (Calbiochem). and the fractions were chilled on ice.

[0071] Biotin-tagged pHLA molecules were prepared in 10 mM Tris pH 8.1, 5 mM NaCl A GE Healthcare rapid desalting column equilibrated in 100 ml of the same buffer was used. Once eluted, the protein-containing fractions were cooled on ice. Then, a protease inhibitor cocktail (Calbiochem) was added. Biotinylation reagent: 1 mM biotin, 5 mM ATP (buffered to pH 8), 7.5 mM MgCl2, and 5 μg / ml BirA enzyme (O'Callaghan et al. l. (1999) Anal. Biochem. 266:9-15) This mixture was then allowed to incubate overnight at room temperature.

[0072] Biotinylated pHLA-A * The 0201 molecule was purified using gel filtration chromatography. GE Healthcare Superdex 75HR 10 / 3 The column was pre-equilibrated with filtered PBS and loaded with 1 ml of the biotinylation reaction mixture. The column was purified using an Akta purification system (GE Healthcare). The plate was developed with BS at 0.5 ml / min. Biotinylated pHLA-A * 0201 minutes The protein eluted as a single peak at approximately 15 ml. Fractions containing the protein were pooled. The mixture was cooled on ice and a protease inhibitor cocktail was added. Protein concentrations were Biotinylated pHLA determined using a Coomassie binding assay (PerBio) -A * Aliquots of 01 molecules were stored frozen at -20°C.

[0073] These immobilized complexes bind both the T cell receptor and the coreceptor CD8αα. Both can be injected into the soluble phase. The pHLA binding properties of soluble TCRs are When TCR is used in either the soluble or immobilized phase, qualitative and quantitative similarities are observed. This is an important control for the partial activity of the soluble species, Biotinylated pHLA complexes are as biologically active as non-biotinylated complexes also suggests.

[0074] The BIAcore 3000™ surface plasmon resonance (SPR) biosensor Refractive index expressed in response units (RU) near the sensor surface in a small flow cell to measure changes in receptor-ligand interactions and their affinity and The BIAcore experiment is a fundamental technique that can be used to analyze the kinetic and molecular parameters of a protein. PBS buffer (Sigma, pH 7) was used as the running buffer at a temperature of 25 °C. The protein sample dilutions were prepared using Streptavidin (1.1–7.5). The amine was immobilized on the flow cell by standard amine coupling techniques. The antibodies were immobilized via the biotin tag and then flowed at a constant flow rate over the surface of different flow cells. The assay is performed by passing soluble TCR through the sera, and the SPR response is measured. It was.

[0075] equilibrium binding constant To determine the equilibrium binding constants, the BIAcore analysis method described above was used. Serial dilutions of the reference MAGE-A4 TCR in soluble heterodimeric form linked with a peptide were The first was approximately 1000 RU of specific GVYDGREHTV HLA-A * 02 The first was coated with 01 conjugate and the second was coated with approximately 1000 RU of a nonspecific conjugate. The response was measured using a constant flow rate of 5 μl per minute over two different flow cells. The data were normalized for each concentration using measurements from control cells. The TA response is plotted against the concentration of TCR sample to determine the equilibrium binding constant, K D Calculate A nonlinear curve fitting model was fitted to the data. (Price & Dwek, Principles es and Problems in Physical Chemistry fo r Biochemists (2nd Edition) 1979, Clarendon Press, Oxford). Reference disulfide-linked soluble MAGE-A4 TCR (Example 2) has a K of approximately 2.00 μM D The same BIAcore data showed T 1 / 2 was about 0.95 seconds.

[0076] Kinetic parameters The BIAcore analysis method described above was also used to determine equilibrium binding constants and dissociation rates. It was done.

[0077] For high affinity TCRs (see Example 4 below), D is the dissociation rate constant, k off , and the binding rate constant, k on was determined by experimentally measuring the equilibrium constant K D is k off / k on was calculated as:

[0078] The first is approximately 1000 RU of specific GVYDGREHTV HLA-A * 0201 composite one was coated with the antibody and the second was coated with approximately 1000 RU of a nonspecific conjugate. TCR was injected into two different cells. The flow rate was set at 50 μl / min. The mice were injected with 250 μl of TCR at a concentration of approximately 1 μM. The response was then measured using a baseline Buffer was allowed to flow until the line returned or >2 hours had elapsed. Kinetic parameters The dissociation phase was calculated using the BIAevaluation software. The decay was fitted to a single exponential decay equation allowing the calculation of the decay period.

[0079] [Example 4] Preparation of high affinity TCRs of the present invention Expression plasmids containing the TCR α and β chains, respectively, were prepared as in Example 1. Did: [Table 4]

[0080] The plasmids were transformed separately into E. coli strain BL21pLysS and expressed as single ampicillin. Ampicillin-resistant colonies were cultured at approximately 0.6–1.2 μg / ml in TYP (ampicillin 100 μg / ml) medium at 37°C. O.D. of 0.8 600 After incubation for 1 h, protein expression was induced with 0.5 mM IPTG. Three hours after transfection, the cells were incubated at 4000 rpm for 30 min in a Beckman J-6B. The cells were then collected by centrifugation for 1 min. The cell pellet was diluted with MgCl2 and DNase I. The inclusion body pellet was dissolved in 25 ml of Bug Buster (Novagen) in the presence of The pellets were centrifuged at 13,000 rpm for 30 minutes in a Beckman J2-21 centrifuge. Then, three detergent washes were performed to remove cell debris and The inclusion body pellet was washed with Triton buffer (50 mM Tris-HCI pH8.0, 0.5% Triton-X100, 200mM Na After homogenization in 10 mM NaEDTA (10 mM Cl), the cells were then homogenized using a Beckman J2- The cells were pelleted by centrifugation at 13,000 rpm for 15 minutes in a 21. Lower buffer: 50 mM Tris-HCl pH 8.0, in 1 mM NaEDTA The detergent and salts were removed by similar washings. Finally, the inclusion bodies were collected at 30 mg. The inclusion body protein yield was 6M. The OD measurements were performed using a Hitachi U-2001 The protein concentration was then calculated using the extinction coefficient.

[0081] Approximately 10 mg of TCR α chain and TCR α chain for each TCR of the present invention were used to ensure complete chain denaturation. The solubilized inclusion bodies of the TCR β chain and 10 mg of the TCR β chain were dissolved in 10 ml of guanidine solution (6 M guanidine hydrochloride). anidine, 50 mM Tris HCl pH 8.1, 100 mM NaCl, 10 mM Fully reduced and denatured TCR chains were diluted in 10 mM EDTA, 10 mM DTT. The guanidine solution containing - 100mM Tris pH 8.1, 400mM L-arginine, 2mM EDT A, injected in 5 M urea. Redox couple (cysteamine hydrochloride and cystamine dihydrochloride). ) was added to a final concentration of 6.6 mM and 3.7 mM, respectively, and after approximately 5 minutes, the denatured The refolded TCR chains were added. The solution was left for about 30 minutes. TCR was measured using Spectrapor1 membrane (Spectrum; product no. 13267 0) was dialyzed against 10 L of H2O for 18-20 hours. After this time, The buffer was exchanged twice into fresh 10 mM Tris pH 8.1 (10 L) and dialyzed. The incubation was continued for approximately another 8 hours at 5°C ± 3°C.

[0082] Soluble TCR was purified by ion exchange using POROS 50HQ anion exchanger. The bound protein was purified by loading it onto a conversion column in an Äkta purification apparatus (G E Healthcare) over 15 column volumes of 10 mM Tris p Degradation products and entrapment products were isolated by elution with a gradient of 0 to 500 mM NaCl in H8.1. The pooled fractions were then stored at 4°C and stained with Coomassie. The soluble fraction was analyzed by SDS-PAGE and then pooled and concentrated. The TCR was pre-equilibrated in PBS buffer (Sigma) from GE Health Purified and characterized using a care Superdex 75HR gel filtration column. The peak eluting at a relative molecular weight of approximately 50 kDa was pooled and the BIAcore table were concentrated before characterization by surface plasmon resonance analysis.

[0083] The TCRs thus prepared against the MAGE-A4 epitope or MAGE-B2 The affinity profile was assessed using the methods of Example 3 and compared to a reference TCR. The results are set out in the table below: [Table 5]

[0084] High affinity TCRs based on combinations of SEQ ID NOs: 10 / 11, 12 / 13, and 14 / 15 were prepared. Attempts were also made to produce

[0085] In the case of TCR A, which has an alpha chain of SEQ ID NO: 10 and a beta chain of SEQ ID NO: 11, In this case, cross-reactivity was observed between MAGE-A1, MAGE-A10 and PRAME. It was not possible to eliminate this cross-reactivity by mutation and selection.

[0086] TCR B combines an alpha chain of SEQ ID NO:12 and a beta chain of SEQ ID NO:13. TCR B could not be folded to form a soluble TCR. Therefore, binding characterization was not possible.

[0087] TCR C combines an alpha chain of SEQ ID NO:14 and a beta chain of SEQ ID NO:15. This TCR was soluble and capable of binding antigen when expressed. However, when expressed in T cells, TCR C showed no activity.

[0088] [Example 5] T cell transduction with parental MAGE-A4 TCR and variant MAGE-A10 TCR Infection (a) By transient transfection of 293T cells via Express-In Lentiviral vector preparation Packaging a lentiviral vector containing a gene encoding the desired TCR To express the vector, a third generation lentiviral packaging system was used. using s-In-mediated transfection (Open Biosystems). 293T cells were transfected with four plasmids (TCR alpha chain- One lentiviral vector containing the P2A-TCR beta chain single ORF gene, and Other components required for constructing infectious but replication-incompetent lentiviral particles The mice were transfected with three plasmids each containing

[0089] For transfection, one T1 of 293T cells in exponential growth phase was used. 50 flasks were harvested and the cells were evenly distributed on the plate with just over 50% The cells were confluent at 3 mL. An aliquot of Express-In was allowed to come to room temperature. Serum-free medium (RPMI1640 + 10mM HEPES) was placed in a sterile 15ml conical 174 μl of Express-In Reagent was placed directly into the serum-free medium. (This provides a 3.6:1 weight ratio of reagent to DNA). Mix thoroughly by inverting the tube 4 times and incubate at room temperature for 5-20 min. It was baited.

[0090] In a separate 1.5 ml microfuge tube, aliquot the premixed packaging mixture. Amount (18 μg of pRSV.REV (Rev expression plasmid), 18 μg of pMDLg / p .RRE (Gag / Pol expression plasmid), 7 μg of pVSV-G (VSV glycoprotein The plasmid DNA is added to a volume of approximately 22 μl (usually containing a plasmid expression plasmid). The DNA mixture was pipetted up and down to ensure uniformity. Approximately 1 mL of Express-In / serum-free medium is added dropwise to the NA mixture, and then After gently pipetting up and down, remove the remaining Express-In / Serum-Free The tubes were inverted 3-4 times and incubated at room temperature for 15-30 minutes. The old medium was removed from the flask of cells. The Express-In / medium / DNA (3 mL) complex was added directly to the bottom of the scoc. Gently place the flask flat over the cells, squeezing them very tightly to ensure dispersion. After 1 min, 22 ml of fresh medium (R10 + HEPES:RPMI 1640, 10% heat inactivated FBS, 1% penicillin / streptomycin / L-glucose 10 mM ethanol, 10 mM HEPES) is added and the flask is carefully placed in the incubator. This was incubated overnight at 37°C / 5% CO2. After 24 hours, the The media containing the caged lentiviral vectors was collected.

[0091] To recover the packaged lentiviral vectors, the cell culture supernatant was The culture medium was filtered through a 0.45 micron nylon syringe filter and diluted with 10,0 The pellet was centrifuged at 100,000g for 18 hours (or at 112,000g for 2 hours) (without disturbing the pellet). The majority of the supernatant is removed (taking care not to drop the supernatant) and the remaining few mL (31 mL per tube) is removed. The pellet was resuspended in 10 ml of supernatant (usually about 2 ml from a starting volume of 1 ml). The mixture was snap frozen in ml aliquots on dry ice and stored at -80°C.

[0092] (b) T cell proliferation with packaged lentiviral vectors containing the gene of interest. Pawnbroker Prior to transduction with the packaged lentiviral vector, blood samples from healthy volunteers were Human T cells (CD8 or CD4 or both depending on requirements) were isolated from the spleen. The cells were counted and cultured in 48-well plates in R 10 in, 1 x 10 per ml 6 Cells (0.5 mL / well) with 3 beads per cell Prewashed anti-CD3 / CD28 antibody-coated microbeads in a ratio of (Dynabeads® T cell expander, Invitrogen en) overnight.

[0093] After overnight stimulation, 0.5 ml of undiluted packaged lentiviral vectors were This was then added to the desired cells, which were then incubated at 37°C / 5% CO2 for 3 days. Three days after transduction, cells were counted and 0.5 × 10 6 cells / ml. Fresh medium containing L-2 was added as needed. Beads were removed 5–7 days after transduction. At 2-day intervals, cells were counted and fresh medium containing IL-2 was replaced or added. The cells were 0.5 × 10 6cells / mL and 1 x 10 6 cells / mL Cells were analyzed by flow cytometry from day 3 and functional assays from day 5. (e.g., ELISpot for IFNγ release, see Example 6) From day 10, or when the cells begin to slow down their division and decrease in size, the cells For storage (1 × 10 in 90% FBS / 10% DMSO) 7 (cells / ml) at least 4×10 6 Aliquots of cells / vial are frozen.

[0094] [Example 6] Activation of MAGE A4 TCR-modified T cells Activation of TCR-transduced cytotoxic T lymphocytes (CTLs) in response to tumor cell lines To demonstrate this, the following assays were performed: IFN-γ production, as seen in the readings for cytotoxic T lymphocyte (CTL) activation, Used it as an outlet.

[0095] ELISPOT reagent Assay medium: 10% FCS (Gibco, Cat. No. 2011-09), 88% R PMI1640 (Gibco, Cat. No. 42401), 1% glutamine (Gibco Catalog No. 25030) and 1% penicillin / streptomycin (Gibco Catalog Log number 15070-063). Washing buffer: 0.01M PBS / 0.05% Tween 20 PBS (Gibco Catalog No. 10010) Related AEC Substrate Set (BD Bioscience, Cat. No. 551951) along with capture and detection antibodies and human IFN-γ PVDF ELISPOT Human IFNγ ELISPOT kit (BD Biosciences) with 96-well plate nce; Catalog Number 551849)

[0096] method Preparation of target cells The target cells used in this method are natural epitope-presenting cells: both HLA-A 2 + MAGE A10 + The target cells were A375 human melanoma cells, which are HLA-A2 + M AGE A10 - HCT116 human colon carcinoma, a marker for inflammatory bowel disease, was used as a negative control. A sufficient number of target cells (50,000 cells / well) were cultured using Megafuge® 1.0 ( The cells were washed three times for 10 min at 1200 rpm in a Heraeus. Then, add 10 6 cells / ml and resuspended.

[0097] Effector cell preparation The effector cells (T cells) used in this method are CD14 and CD25 Microbead kits (Miltenyi Biotech catalog number 130 each) -050-201 and 130-092-983) from venous blood of healthy volunteers. Peripheral blood mononuclear cells (PBMCs) were obtained by negative selection from freshly isolated peripheral blood The cells were cultured with anti-CD3 / CD28 coated beads (D ynabeads® T cell expander, Invitrogen ) and expressing the whole αβTCR of interest (based on the construct described in Example 5). The mice were transduced with lentivirus carrying the gene encoding the IL-2 inhibitor 50 U / mL. The cells were then grown in culture medium for between 10 and 13 days after transduction. After being placed in assay medium, the cells were then analyzed using Megafuge® 1.0 (Hermitt The cells were then washed by centrifugation at 1200 rpm for 10 min in a centrifuge. and resuspended in assay medium at 4x the final required concentration.

[0098] Plates were prepared as follows: 100 μL of anti-IFN-γ capture antibody was added to one plate. The diluted samples were then placed in 100 μL of sterile PBS per well. The plate was then incubated overnight at 4°C. After incubation, the plate was washed (Program 1, Plate Type 2, Ultra The plate was washed with a Dynex Wash Plus 96-well plate washer to remove the capture antibody. The plates were then incubated for 30 min at 4°C for 10 min at 4°C for 2 h by adding 200 μL of assay medium to each well. The assay medium was then blocked with PBS and incubated at room temperature for 2 hours. Washing rate from program 1, plate type 2, Ultrawash Plus 9 6-well plate washer (Dynex) and all remaining medium was removed for ELISPOT plate The residue was removed by flicking and tapping on a paper towel.

[0099] The components of the assay were then added to the ELISPOT plate in the following order: 10 target cells in 50 μL 6 cells / ml (total of 50,000 target cells / well ) 50μL medium (assay medium) 50 μL effector cells (20,000 TCR-transduced PBL cells / well)

[0100] The plates were then incubated overnight (37°C / 5% CO2). The plates were washed three times with washing buffer (Program 1, Plate Type 2, Ultrawa sh Plus 96-well plate washer (Dynex), tapped on paper towel The plates were then dried to remove excess wash buffer. 100 μl of primary detection antibody was then added to the plates. The primary detection antibody was added to each well at the dilution specified in the manufacturer's instructions. Dilute in 10 mL of dilution buffer (volume required for a single plate) using The plates were then incubated at room temperature for at least 2 hours before being washed with a washing buffer. The plates were washed three times with Ultrawash Plus (Program 1, Plate Type 2, Ultrawash Plus 96-well plate washer, Dynex); excess wash buffer is removed by washing the plate with paper. - Removed by tapping on a towel.

[0101] For secondary detection, add 100 μL of diluted streptavidin-HRP to each well. The plate was incubated at room temperature for 1 hour with Streptavidin. Dilute N-HRP in 10 mL of dilution buffer using the dilution specified in the manufacturer's instructions. The plates were then washed with a wash buffer. The plates were washed three times in the buffer (program 1, plate type 2, Ultrawash Plus 96-well plate washer (Dynex), gently tapped on paper towel to wash excess The washing buffer was removed. The plate was then pre-washed with PBS and 200 μL was added to each well. Wash twice by gently shaking off the buffer and patting on a paper towel. The excess buffer was removed by tapping. Within 15 minutes before use, 1 drop (20 uL) of AE C chromogen was added to each 1 ml of AEC substrate and mixed. 10 ml for each plate This solution was prepared; 100 μL was added per well. The plate was then Protect from light using foil and allow the spot to develop a steady color, which usually occurs within 5-20 minutes. The plate is washed in tap water to terminate the color reaction. They were shaken dry before being split into three components. The plates were then left at room temperature for a short After allowing to dry for at least 2 hours, the plates were read into an Immunospot® plate reader. Cellular Technology Limited (CTL) The pots were counted.

[0102] [Example 7] Identification of binding motifs by substitution with all alternative amino acids The amino acid residue at each position is sequentially sequenced with all 19 alternative naturally occurring amino acids. A variant of the replaced natural MAGE-A4 peptide was obtained, thereby 171 peptides were prepared in the study. Natural peptides and peptides with amino acid substitutions were The peptide was pulsed onto antigen-presenting cells and measured using an ELISpot assay. Interferon-γ (IFNγ) production regulates the activation of TCR4-transduced T cells The essential positions were used as readouts for the natural peptide. was defined as a greater than 50% decrease in T cell activity on

[0103] ELISpot assays were performed as described in Example 6.

[0104] The permissible residues at each position in the peptide are shown below. The underlined amino acids are , represents the naturally occurring residue at that position in the peptide.

[0105] [Table 6]

[0106] Therefore, HLA-A on the surface of antigen-presenting cells * It appears that when complexed with 0201, MAGE A4 TCR4 makes contact with at least V2 Y3 and D4 of the peptide (SEQ ID NO:1). The claims as of the filing are as follows: [Claim 1] 1. A T cell receptor (TCR) having the property of binding to GVYDGREHTV (SEQ ID NO: 1) complexed with HLA-A*0201 with a dissociation constant of from about 0.05 μM to about 20.0 μM when measured by surface plasmon resonance at 25° C. between pH 7.1 and 7.5 using a soluble form of the TCR, and having at least 10-fold selectivity for binding to SEQ ID NO: 1 complexed with HLA-A*0201 over binding to GVYDGAYVSV (SEQ ID NO: 2) complexed with HLA-A*0201, said TCR comprising a TCR alpha chain variable domain and a TCR beta chain variable domain, said TCR variable domain making contacts with at least residues V2, Y3 and D4 of GVDGKSDSV (SEQ ID NO: 1). [Claim 2] The TCR of claim 1, which is an alpha-beta heterodimer having an alpha chain TRAV10+TRAC constant domain sequence and a beta chain TRBV24-1+TRBC-2 constant domain sequence. [Claim 3] The TCR of claim 1, which is in a single chain format of the type Vα-L-Vβ, Vβ-L-Vα, Vα-Cα-L-Vβ, or Vα-L-Vβ-Cβ, where Vα and Vβ are the TCR alpha variable region and the TCR beta variable region, respectively, Cα and Cβ are the TCR alpha constant region and the TCR beta constant region, respectively, and L is a linker sequence. [Claim 4] 4. A TCR according to any one of claims 1 to 3, linked to a detectable label, a therapeutic agent or a PK modifying moiety. [Claim 5] the alpha chain variable domain comprises an amino acid sequence having at least 80% identity to the sequence of amino acid residues 1 to 105 of SEQ ID NO:3, with reference to the numbering shown in SEQ ID NO:3 [Table 7] and / or the beta chain variable domain comprises an amino acid sequence having at least 80% identity to the sequence of amino acid residues 1 to 105 of SEQ ID NO: 4, with reference to the numbering shown in SEQ ID NO: 4. [Table 8] A TCR described in any one of claims 1 to 4, having at least one of the following mutations. [Claim 6] the alpha chain variable domain comprises the amino acid sequence of amino acid residues 1 to 105 of SEQ ID NO: 3 or SEQ ID NO: 5 or SEQ ID NOs: 7 to 8, or an amino acid sequence in which the amino acid residues 1 to 27, 34 to 47 and 54 to 90 have at least 90% or 95% identity to the amino acid residues 1 to 27, 34 to 47 and 54 to 90 of SEQ ID NO:3 or SEQ ID NO:5 or SEQ ID NO:7 to 8, respectively, and the amino acid residues 28 to 34, 48 to 53 and 91 to 105 have at least 90% or 95% identity to the amino acid residues 28 to 33, 48 to 53 and 91 to 105 of SEQ ID NO:3 or SEQ ID NO:5 or SEQ ID NO:7 to 8, respectively 6. The TCR of any one of claims 1 to 5, comprising: [Claim 7] the alpha chain variable domain comprises the amino acid sequence of amino acid residues 1 to 105 of SEQ ID NO: 7 or SEQ ID NO: 8, or an amino acid sequence in which the amino acid residues 1 to 27, 34 to 47 and 55 to 89 have at least 90% or 95% identity to the sequences of amino acid residues 1 to 27, 34 to 47 and 55 to 89 of SEQ ID NO: 7 or SEQ ID NO: 8, respectively, and the amino acid residues 28 to 33, 48 to 53 and 91 to 105 have at least 90% or 95% identity to the sequences of amino acid residues 28 to 33, 48 to 53 and 91 to 105 of SEQ ID NO: 7 or SEQ ID NO: 8, respectively. 8. The TCR of any one of claims 1 to 7, comprising: [Claim 8] In the alpha chain variable domain (i) the sequence of amino acid residues 1 to 27 of which (a) has at least 90% identity to the sequence of amino acid residues 1 to 26 of SEQ ID NO: 3; or (b) has one, two or three amino acid residues inserted or deleted relative to the sequence of (a); (ii) the sequence of amino acid residues 28 to 33 is VSPFSN; (iii) the sequence of amino acid residues 34 to 47 of which (a) has at least 90% identity to the sequence of amino acid residues 33 to 47 of SEQ ID NO: 3; or (b) has one, two or three amino acid residues inserted or deleted relative to the sequence of (a); (iv) the sequence of amino acid residues 48 to 53 is LTIMTF, LTRMTF, LTIVTF, or LTILTF; (v) the sequence of amino acid residues 54 to 90 has at least 90% identity to the sequence of amino acid residues 55 to 89 of SEQ ID NO: 3, or has one, two or three insertions, deletions or substitutions relative thereto; (vi) the sequence of amino acids 91 to 105 is CVVSGGTDSWGKLQF; A TCR described in any one of claims 1 to 7. [Claim 9] the beta chain variable domain is an amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 6 or SEQ ID NO: 9, or an amino acid sequence in which amino acid residues 1 to 45, 51 to 67 and 74 to 109 have at least 90% or 95% identity to the sequence of amino acid residues 1 to 45, 51 to 67 and 74 to 109 of SEQ ID NO: 4 or SEQ ID NO: 6 or SEQ ID NO: 9, respectively, and amino acid residues 46 to 50, 68 to 73 and 109 to 123 have at least 90% or 95% identity to the sequence of amino acid residues 46 to 50, 68 to 73 and 109 to 123 of SEQ ID NO: 4 or SEQ ID NO: 6 or SEQ ID NO: 9, respectively. 9. The TCR of any one of claims 1 to 8, comprising: [Claim 10] In the beta chain variable domain (i) the sequence of amino acid residues 1 to 45 of which (a) has at least 90% identity to the amino acid sequence of residues 1 to 26 of SEQ ID NO: 4; or (b) has one, two or three amino acid residues inserted or deleted relative to the sequence of (a); (ii) the sequence of amino acid residues 46 to 50 is KGHDR; (iii) the sequence of amino acid residues 51 to 67 of which (a) has at least 90% identity to the sequence of amino acid residues 51 to 67 of SEQ ID NO: 4; or (b) has one, two or three amino acid residues inserted or deleted relative to the sequence of (a); (iv) the sequence of amino acid residues 68 to 73 is SFDVK; (v) the sequence of amino acid residues 54 to 90 of which (a) has at least 90% identity to the sequence of amino acid residues 54 to 90 of SEQ ID NO: 4; or (b) has one, two or three amino acid residues inserted or deleted relative to the sequence of (a); (vi) the sequence of amino acids 109 to 123 is CATSGQGAYNEQFF or CATSGQGAYREQFF; A TCR described in any one of claims 1 to 9. [Claim 11] A nucleic acid encoding a TCR according to any one of claims 1 to 10. [Claim 12] 13. An isolated or non-naturally occurring cell, in particular a T cell, presenting a TCR according to any one of claims 1 to 12. [Claim 13] (a) a TCR expression vector comprising the nucleic acid of claim 13 in a single open reading frame or in two different open reading frames encoding the alpha chain and the beta chain, respectively; or (b) a first expression vector comprising a nucleic acid encoding the alpha chain of a TCR according to any one of claims 1 to 12, and a second expression vector comprising a nucleic acid encoding the beta chain of a TCR according to any one of claims 1 to 12. Cells that harbor [Claim 14] A pharmaceutical composition comprising a TCR according to any one of claims 1 to 10, a nucleic acid according to claim 11, or a cell according to claim 12 or claim 13, together with one or more pharma- ceutically acceptable carriers or excipients. [Claim 15] A TCR as claimed in any one of claims 1 to 12, a nucleic acid as claimed in claim 13 or a cell as claimed in claim 14 or claim 15 for use in medicine. [Claim 16] 16. The TCR, nucleic acid or cell for use according to claim 15 for use in a method for treating cancer.

[0107] SEQ ID NO: 1 MAGE A4 epitope [ka] SEQ ID NO:2 MAGE B2 epitope [ka] SEQ ID NO: 3 Alpha variable chain [ka] SEQ ID NO: 4 Beta variable chain [ka] SEQ ID NO: 5 Alpha chain soluble form [ka] SEQ ID NO:6 Beta chain soluble form [ka] SEQ ID NO: 7 Mutant alpha variable chain [ka] SEQ ID NO:8 Mutant alpha variable chain [ka] SEQ ID NO: 9 Mutant beta variable chain [ka] SEQ ID NO: 10 Alpha chain soluble form [ka] SEQ ID NO:11 Beta chain soluble form [ka] SEQ ID NO:12 Alpha chain soluble form [ka] SEQ ID NO:13 Beta chain soluble [ka] SEQ ID NO:14 Alpha chain soluble form [ka] SEQ ID NO:15 Beta chain soluble form [ka]

Claims

1. A T cell receptor (TCR) that binds to GVYDGREHTV (SEQ ID NO: 1) complexed with HLA-A*0201, the TCR comprising a TCR alpha chain variable domain and a TCR beta chain variable domain; alpha CDR1 is VSPFSN; alpha CDR2 is LTIMTF or LTIVTF or LTILTF, and alpha CDR3 is CVVSGGTDSWGKLQF, and beta CDR1 is KGHDR; beta CDR2 is SFDVK, and A TCR in which beta CDR3 is CATSGQGAYEEQFF.

2. 2. The TCR of claim 1, which is an alpha-beta heterodimer having an alpha chain TRAV10+TRAC constant domain sequence and a beta chain TRBV24-1+TRBC-2 constant domain sequence.

3. A TCR as described in claim 1, which is in a single-chain format of type Vα-L-Vβ, Vβ-L-Vα, Vα-Cα-L-Vβ, or Vα-L-Vβ-Cβ, wherein Vα and Vβ are the TCR α variable region and TCR β variable region, respectively, Cα and Cβ are the TCR α constant region and TCR β constant region, respectively, and L is a linker sequence.

4. 4. The TCR of any one of claims 1 to 3, conjugated to a detectable label, a therapeutic agent or a PK-modifying moiety.

5. the TCR alpha chain variable domain comprises an amino acid sequence having at least 80% identity to the amino acid sequence of the TCR alpha chain variable domain of SEQ ID NO:3; and / or 5. A TCR according to any one of claims 1 to 4, wherein the TCR beta chain variable domain comprises an amino acid sequence having at least 80% identity to the amino acid sequence of the TCR beta chain variable domain of SEQ ID NO:

4.

6. The TCR, (i) the sequence of amino acid residues 1 to 27 of which has at least 90% identity to the sequence of amino acid residues 1 to 27 of SEQ ID NO:3; (ii) the sequence of amino acid residues 28 to 33 is VSPFSN; (iii) the sequence of amino acid residues 34 to 47 of which has at least 90% identity to the sequence of amino acid residues 34 to 47 of SEQ ID NO:3; (iv) the sequence of amino acid residues 48 to 53 is LTIMTF or LTIVTF or LTILTF; (v) the sequence of amino acid residues 54 to 90 has at least 90% identity to the sequence of amino acid residues 54 to 90 of SEQ ID NO: 3; and (vi) the sequence of amino acids 91 to 105 is CVVSGGTDSWGKLQF; A TCR according to any one of claims 1 to 5, comprising the TCR alpha chain variable domain.

7. A TCR described in any one of claims 1 to 6, wherein the TCR comprises a TCR alpha chain variable domain having an amino acid sequence of SEQ ID NO: 3, 7, or 8.

8. The TCR, (i) the sequence of amino acid residues 1 to 45 of which has at least 90% identity to the amino acid sequence of residues 1 to 45 of SEQ ID NO:4; (ii) the sequence of amino acid residues 46 to 50 is KGHDR; (iii) the sequence of amino acid residues 51 to 67 of which has at least 90% identity to the sequence of amino acid residues 51 to 67 of SEQ ID NO: 4; (iv) the sequence of amino acid residues 68 to 72 is SFDVK; (v) the sequence of amino acid residues 73 to 109 has at least 90% identity to the sequence of amino acid residues 73 to 109 of SEQ ID NO: 4; and (vi) the sequence of amino acids 110 to 123 is CATSGQGAYEEQFF; A TCR according to any one of claims 1 to 7, comprising the TCR beta chain variable domain.

9. The TCR of any one of claims 1 to 8, wherein the TCR comprises a TCR beta chain variable domain having the amino acid sequence of SEQ ID NO:

9.

10. A TCR described in any one of claims 1 to 9, wherein the TCR comprises a TCR alpha chain variable domain having an amino acid sequence selected from the group consisting of SEQ ID NO: 3, 7, and 8, and a TCR beta chain variable domain having the amino acid sequence of SEQ ID NO:

9.

11. A TCR described in any one of claims 1 to 10, wherein the TCR comprises a TCR alpha chain variable domain having the amino acid sequence of SEQ ID NO: 8 and a TCR beta chain variable domain having the amino acid sequence of SEQ ID NO:

9.

12. A cell presenting a TCR encoded by a nucleic acid, the nucleic acid comprising: (A)(i) the sequence of amino acid residues 1 to 27 has at least 90% identity to the sequence of amino acid residues 1 to 27 of SEQ ID NO:3; (ii) the sequence of amino acid residues 28 to 33 is VSPFSN; (iii) the sequence of amino acid residues 34 to 47 has at least 90% identity to the sequence of amino acid residues 33 to 47 of SEQ ID NO:3; (iv) the sequence of amino acid residues 48 to 53 is LTIMTF or LTIVTF or LTILTF; (v) the sequence of amino acid residues 54-90 has at least 90% identity to the sequence of amino acid residues 54-90 of SEQ ID NO:3; and (vi) the sequence of amino acids 91 to 105 is: CVVSGGTTDSWGKLQF and a TCR alpha chain variable domain, (B)(i) the sequence of amino acid residues 1 to 45 has at least 90% identity to the amino acid sequence of residues 1 to 45 of SEQ ID NO:4; (ii) the sequence of amino acid residues 46 to 50 is KGHDR; (iii) the sequence of amino acid residues 51-67 has at least 90% identity to the sequence of amino acid residues 51-67 of SEQ ID NO:4; (iv) the sequence of amino acid residues 68 to 72 is SFDVK; (v) the sequence of amino acid residues 73 to 109 has at least 90% identity to the sequence of amino acid residues 73 to 109 of SEQ ID NO:4; and (vi) the sequence of amino acids 110 to 123 is: CATSGQGAYEEQFF a TCR beta chain variable domain, a cell encoding a TCR comprising A cell, wherein said TCR binds to GVYDGREHTV (SEQ ID NO: 1) complexed with HLA-A*0201.

13. The cell of claim 12, wherein the nucleic acid encoding the TCR encodes a TCR comprising a TCR alpha chain variable domain selected from the group consisting of the amino acid sequences of SEQ ID NO: 3, 7, and 8, and a TCR beta chain variable domain having the amino acid sequence of SEQ ID NO:

9.

14. The cell of claim 12 or 13, wherein the nucleic acid encoding the TCR encodes a TCR comprising a TCR alpha chain variable domain having the amino acid sequence of SEQ ID NO:8 and a TCR beta chain variable domain having the amino acid sequence of SEQ ID NO:

9.

15. A pharmaceutical composition comprising a TCR according to any one of claims 1 to 11, a cell according to any one of claims 12 to 14, together with one or more pharma- ceutically acceptable carriers or excipients.

16. A TCR according to any one of claims 1 to 11, or a cell according to any one of claims 12 to 14, for use in medicine.

17. 17. The TCR or cell of claim 16 for use in a method of treating cancer.

Citation Information

Patent Citations

  • T-cell receptor and nucleic acid encoding the receptor

    JP2013126415A